mRNA and protein expression for novel GABA\textsubscript{A} receptors $\theta$ and $\rho2$ are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway

SH Fatemi\textsuperscript{1,2,3}, TD Folsom\textsuperscript{1}, RJ Rooney\textsuperscript{4} and PD Thuras\textsuperscript{5}

Fragile X mental retardation protein (FMRP) is an RNA-binding protein that targets $\sim$5% of all mRNAs expressed in the brain. Previous work by our laboratory demonstrated significantly lower protein levels for FMRP in lateral cerebella of subjects with schizophrenia, bipolar disorder and major depression when compared with controls. Absence of FMRP expression in animal models of fragile X syndrome (FXS) has been shown to reduce expression of gamma-aminobutyric acid A (GABA\textsubscript{A}) receptor mRNAs. Previous work by our laboratory has found reduced expression of FMRP, as well as multiple GABA\textsubscript{A} and GABA\textsubscript{B} receptor subunits in subjects with autism. Less is known about levels for GABA\textsubscript{A} subunit protein expression in brains of subjects with schizophrenia and mood disorders. In the current study, we have expanded our previous studies to examine the protein and mRNA expression of two novel GABA\textsubscript{A} receptors, theta (GABR\textsubscript{\theta}) and rho 2 (GABR\textsubscript{\rho2}) as well as FMRP, and metabotropic glutamate receptor 5 (mGluR5) in lateral cerebella of subjects with schizophrenia, bipolar disorder, major depression and healthy controls, and in superior frontal cortex (Brodman Area 9 (BA9)) of subjects with schizophrenia, bipolar disorder and healthy controls. We observed multiple statistically significant mRNA and protein changes in levels of GABR\textsubscript{\theta}, GABR\textsubscript{\rho2}, mGluR5 and FMRP molecules including concordant reductions in mRNA and proteins for GABR\textsubscript{\theta} and mGluR5 in lateral cerebella of subjects with schizophrenia; for increased mRNA and protein for GABR\textsubscript{\rho2} in lateral cerebella of subjects with bipolar disorder; and for reduced mRNA and protein for mGluR5 in BA9 of subjects with bipolar disorder. There were no significant effects of confounds on any of the results.

Translational Psychiatry (2013) 3, e271; doi:10.1038/tp.2013.46; published online 18 June 2013

Introduction

Impairment of the gamma-aminobutyric acid (GABA) signaling system is believed to partially account for behavioral and cognitive deficits associated with schizophrenia and mood disorders.$^{1,2}$ Reduction of GABA\textsubscript{A} mediated signal transmission has also been associated with anxiety, panic, impaired learning and memory.$^{3-5}$ GABA\textsubscript{A} receptors are responsible for mediating the fast inhibitory action of GABA,$^{6}$ and are important sites for clinical action of a number of drugs including benzodiazepines, barbiturates and anesthetics. Recent work has suggested that proper GABAergic neurotransmission is required for network oscillations that facilitate the processing of information both in and between various brain regions and that this may be required for normal cognition.$^{1}$ Altered expression of GABA\textsubscript{A} receptor subunits could impair these oscillations and result in improper cognitive function. Little is currently known about GABA\textsubscript{A} receptor subunit expression in schizophrenia and mood disorders, although it is likely that changes in GABA\textsubscript{A} receptor expression would result in reduced GABAergic transmission.

Recent evidence$^{7-9}$ provides a linkage between GABA neurotransmission and fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein that has been estimated to regulate translation of 842 transcripts in the brain.$^{10}$ In animal models of fragile X syndrome (FXS), the absence of FMRP is accompanied by reduced mRNA expression of GABA\textsubscript{A} receptor subunits including alpha 1 ($\alpha1$), $\alpha2$, $\alpha4$, beta 1 ($\beta1$), $\beta2$, delta ($\delta$), gamma 1 ($\gamma1$) and $\gamma2$ in frontal cortex, whereas there was no change in the cerebellum.$^{7-9}$ A functional consequence of this reduced expression has been observed in fragile X mental retardation 1 (Fmr1)-knocked out mice that display impaired GABAergic signaling in striatal neurons, as measured by increased frequency of spontaneous and miniature inhibitory postsynaptic currents and reduced paired pulse ratio of inhibitory postsynaptic currents.$^{11}$

FMRP normally represses metabotropic glutamate receptor 5 (mGluR5) signaling, whereas the absence of FMRP has been hypothesized to lead to unregulated mGluR5 signaling, and ultimately result in the various abnormal phenotypes

$^1$Division of Neuroscience Research, Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA; $^2$Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA; $^3$Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA; $^4$Genome Explorations, Memphis, TN, USA and $^5$VA Medical Center, Department of Psychiatry, Minneapolis, MN, USA

Correspondence: Dr SH Fatemi, Division of Neuroscience Research, Department of Psychiatry, University of Minnesota Medical School, 420 Delaware St SE, MMC 392, Minneapolis, MN 55455, USA.

E-mail: fatem002@umn.edu

Keywords: bipolar disorder; FMRP; GABR\textsubscript{\rho2}; GABR\textsubscript{\theta}; mGluR5; schizophrenia

Received 27 February 2013; revised 11 April 2013; accepted 22 April 2013
associated with FXS. Animal studies using antagonists of the mGluR5 receptor have rescued learning and behavioral deficits associated with FXS, and reduced seizures in FMR1-knock out mice.

Recently, we reported on reduced protein expression of FMRP in lateral cerebellum from subjects with schizophrenia, bipolar disorder and major depression. These results are novel, as gene association studies have not identified fragile X mental retardation 1 (FMR1), the gene that codes FMRP, as a candidate gene for schizophrenia. Kovács et al. found that age of onset and IQ predicted FMRP levels, but chlorpromazine-equivalent antipsychotic dose did not. Importantly, none of the study subjects showed the CGG triplet expansion that normally causes silencing of the FMR1 gene in subjects with FXS. Combined with our findings of reduced FMRP expression in the cerebellar vermis and prefrontal cortex of subjects with autism, who were not comorbid for FXS, reduction of FMRP expression may be a hallmark of multiple psychiatric disorders.

Based on the evidence from animal models that decrease in FMRP expression results in reduced expression of GABA<sub>A</sub> receptor subunit mRNA and our finding of significantly reduced FMRP in cerebella of subjects with schizophrenia and mood disorders, we hypothesized that we would observe reduced expression of the GABA<sub>A</sub> receptor subunits in lateral cerebella from the same diagnostic groups. An initial screen of several GABA receptor subunits in lateral cerebella of subjects with schizophrenia, bipolar disorder and major depression found reductions in GABA<sub>A</sub> receptor subunits one and two (GABBR1 and GABBR2). Here, we report novel findings regarding alterations in levels of mRNA and protein for GABA<sub>A</sub> receptor theta (GABR<sub>θ</sub>) and GABA<sub>A</sub> receptor rho 2 (GABBR<sub>2</sub>), as well as mGluR5 and FMRP levels in the lateral cerebellum from the same diagnostic groups. An initial screen of several GABA receptor subunits in lateral cerebella of subjects with schizophrenia, bipolar disorder and major depression found reductions in GABA<sub>A</sub> receptor subunits one and two (GABBR1 and GABBR2).

Materials and methods

Brain procurement. The Institutional Review Board of the University of Minnesota—School of Medicine has approved this study. Post-mortem lateral cerebella were obtained from the McLean 74 Cohort, Harvard Brain and Tissue Resource Center. DSM-IV diagnoses were established prior to death by psychiatrists using information from all available medical records and family interviews. Details regarding the subject selection, demographics, diagnostic process and tissue processing were collected by the Stanley Medical Research Foundation, and the Harvard Brain and Tissue Resource Center. The Stanley collection consisted of 15 subjects with schizophrenia, 15 with bipolar disorder, 14 with major depression without psychotic features and 14 normal controls (Table 1). All groups were matched for age, sex, race, post-mortem interval and hemispheric side.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting. Brain tissue was prepared as previously described. For lateral cerebellum, 60 μg of tissue was used, whereas for BA9, 30 μg of tissue was used. For mGluR5 and FMRP, we used 6% resolving gels, whereas for GABR<sub>θ</sub>, GABR<sub>2</sub>, neuronal-specific enolase (NSE) and β-actin we used 10% resolving gels. We minimized interblot variability by including samples from subjects of each group (control, schizophrenia, bipolar disorder and major depression) on each gel. Samples were run in duplicate. Samples were electrophoresed for 15 min at 75 V, followed by 55 min at 150 V. Samples were then electrophoretically transferred onto nitrocellulose membranes for 2 h at 300 mAmp at 4 °C. Blots were blocked with 0.2% I-Block (Tropix, Bedford, MA, USA) in phosphate-buffered saline with 0.3% Tween 20 for 1 h at room temperature (RT), followed by an overnight incubation in primary antibodies at 4 °C. The primary antibodies used were anti-GABR<sub>θ</sub>, anti-GABR<sub>2</sub>, anti-mGluR5 and anti-FMRP.

| Table 1 | Demographic information for the four diagnostic groups from Stanley Medical Research Institute |
|---------|-------------------------------------------------|
| Age     | Bipolar | Control | Schizophrenia | Depression | F or \( \chi^2 \) | P |
| 42.33 (11.72) | 46.64 (9.46) | 44.53 (13.11) | 46.57 (9.66) | 0.49<sup>a</sup> | 0.69 |
| Sex     | F, 9M   | 5F, 9M   | 6F, 9M       | 6F, 8M     | 0.15<sup>b</sup> | 0.99 |
| Race    | 14W, 1B | 13W, 1B  | 12W, 3A      | 14W        | 14.12<sup>b</sup> | 0.12 |
| PMI     | 32.53 (16.12) | 24.5 (9.85) | 33.67 (14.62) | 27.57 (11.13) | 1.51<sup>b</sup> | 0.22 |
| pH      | 6.18 (0.23) | 6.26 (0.25) | 6.16 (0.26)  | 6.18 (0.23) | 0.51<sup>b</sup> | 0.68 |
| Side of brain | 7L, 8R | 7L, 7R   | 9L, 6R       | 9L, 5R     | 1.20<sup>b</sup> | 0.75 |
| Brain weight | 1441.2 (171.5) | 1511 (165.4) | 1471.7 (108.2) | 1443.57 (127.56) | 0.71<sup>b</sup> | 0.55 |
| Family hx | 0.93 (0.8)  | 0.13 (0.52) | 1.13 (0.83)  | 0.73 (0.46) | 27.19<sup>b</sup> | 0.0001 |
| Suicidal death | 9 (5 Violent) | 0 | 6 (2 Violent) | 9 (4 Violent) | 14.04<sup>b</sup> | 0.029 |
| Drug/Alc hx | 0.8 (0.77) | 0.36 (0.74) | 0.53 (0.74)  | 0.43 (0.64) | 5.08<sup>b</sup> | 0.45 |
| Age of onset | 21.47 (8.35) | — | 23.2 (7.94)  | 33.36 (13.68) | 3.63<sup>b</sup> | 0.001 |
| Duration of illness | 20.13 (9.67) | — | 21.67 (11.24) | 12.29 (11.37) | 2.47<sup>b</sup> | 0.10 |
| Severity of substance abuse | 2.27 (1.98) | 0.14 (0.54) | 1.20 (1.86)  | 1.16 (2.04) | 22.21<sup>b</sup> | 0.10 |
| Severity of alcohol abuse | 2.27 (1.98) | 1.14 (1.03) | 1.47 (1.59)  | 1.93 (2.02) | 8.52<sup>b</sup> | 0.85 |
| Fluphenazine (lifetime) | 20 826.67 (24 015.96) | — | 52 266.67 (62 061.57) | — | 6.21<sup>a</sup> | 0.019 |

<sup>a</sup>ANOVA. <sup>b</sup>χ<sup>2</sup> test. Bold values indicate significant (P<0.05) values.
Table 2: Demographic information for the three diagnostic groups from the McLean 74 Cohort

|                   | Bipolar        | Control       | Schizophrenia | F, 1 or $\chi^2$ | P     |
|-------------------|----------------|---------------|---------------|------------------|-------|
| Age (years)       | 61.75 (19.20)  | 58.59 (15.12) | 60.71 (12.07) | 0.24             | 0.79  |
| Sex               | 4M:15F         | 17M:12F       | 14M:6F        | 10.38            | 0.006 |
| PMI (months)      | 22.25 (5.39)   | 21.76 (3.85)  | 23.86 (7.20)  | 0.92             | 0.41  |
| pH                | 6.45 (0.76)    | 6.45 (0.17)   | 6.49 (0.30)   | 0.07             | 0.93  |
| Side of brain     | 10L:9R         | 14L:15R       | 10L:10R       | 0.087            | 0.96  |
| Suicide death     | 4 (1 violent)  | 0             | 0             | 6.41             | 0.027 |
| Drug/Alc hx       | 0.42 (0.51)    | 0.69 (0.66)   | 0.30 (0.47)   | 6.84             | 0.15  |
| Severity of substance abuse | 0.58 (1.39)  | 0.41 (0.95)   | 0.70 (1.45)   | 0.33             | 0.72  |
| Severity of alcohol abuse | 0.95 (1.43)  | 0.86 (1.73)   | 0.60 (1.23)   | 0.39             | 0.75  |
| Age of onset      | 23.53 (7.67)   |               | 20.52 (3.52)  | 1.45             | 0.16  |
| Duration of illness | 39.69 (18.27) |               | 40.18 (12.09) | 0.091            | 0.93  |
| Use of MS         | 9              |               | 1             | 9.17             | 0.002 |

Abbreviation: MS, mood stabilizer.

*ANOVA, $t$-test, *t*-test for bipolar versus schizophrenia.

Bold values indicate significant ($P < 0.05$) values.

Statistical analysis. All protein measurements for each group were normalized against $\beta$-actin and NSE, and expressed as ratios of GABR/R$\beta$-actin, GABR2/$\beta$-actin, FMRP/$\beta$-actin, mGluR5/$\beta$-actin, GABR/R/NSE, GABR2/NSE, FMRP/NSE and mGluR5/NSE. Statistical analysis was performed as previously described with $P < 0.05$ considered significant. Group comparisons were conducted using analysis of variance (ANOVA). Follow-up independent $t$-tests were then conducted if the results were significant. Group differences on possible confounding factors were explored using $\chi^2$ tests for categorical variables, and ANOVA for continuous variables. Where group differences were found, analysis of covariance was used to explore these effects on group differences for continuous variables, and factorial ANOVA with interaction terms for categorical variables. All analyses were conducted using SPSS v.17 (SPSS, Chicago, IL, USA).

Results

Western blotting results for GABR, GABR2, FMRP and mGluR5 in the lateral cerebellum. All protein measurements were normalized against $\beta$-actin or NSE. In lateral cerebella, ANOVA identified group differences for GABR/R/$\beta$-actin (F(3,48) = 5.49, $P < 0.003$), GABR2/NSE (F(3,48) = 5.61, $P < 0.002$), GABR2/$\beta$-actin (F(3,40) = 2.90, $P < 0.047$), GABR2/NSE (F(3,40) = 3.05, $P < 0.039$), mGluR5 monomer/$\beta$-actin (F(3,46) = 4.15, $P < 0.011$) and mGluR5 monomer/NSE (F(3,46) = 5.18, $P < 0.004$) (Figure 1; Table 3). There was a group difference for FMRP/NSE (F(3,50) = 4.93, $P < 0.004$) (Figure 1; Table 3).

Follow-up $t$-tests found significant reductions in protein for GABR/R/$\beta$-actin ($P < 0.001$), GABR2/NSE ($P < 0.001$), mGluR5 monomer/$\beta$-actin ($P < 0.050$), mGluR5 monomer/NSE ($P < 0.030$) and FMRP/NSE ($P < 0.001$) in subjects with schizophrenia (Table 3; Figures 2 and 3). In lateral cerebella from subjects with bipolar disorder, there were significant reductions in GABR/R/$\beta$-actin ($P < 0.012$), GABR2/NSE ($P < 0.005$), mGluR5 monomer/$\beta$-actin ($P < 0.001$), mGluR5 monomer/NSE ($P < 0.004$) and FMRP/NSE ($P < 0.003$), and significant increased expression of GABR2/$\beta$-actin ($P < 0.0044$) and GABR2/NSE ($P < 0.009$) (Table 3;...
increased expression of GABR and mGluR5 in BA9.

Western blotting results for GABR and mGluR5 were no significant changes in protein levels of mGluR5 dimer/NSE (0.93 ± 0.085) and FMRP/NSE (0.04 ± 0.017) (Table 3; Figures 2 and 3). There were no significant changes in protein levels of mGluR5 dimer in lateral cerebellum.

Western blotting results for GABR, GABR2, FMRP and mGluR5 in BA9. In BA9, ANOVA identified group differences for GABR/β-actin (F(2,64) = 4.04, P < 0.022), GABR/β-actin (F(2,62) = 4.54, P < 0.014), mGluR5 monomer/β-actin (F(2,63) = 10.72, P < 0.001), mGluR5 monomer/NSE (F(2,63) = 8.14, P < 0.001), FMRP/β-actin (F(2,59) = 3.85, P < 0.027) and FMRP/NSE (F(2,60) = 4.26, P < 0.014) (Figure 1; Table 4). Follow-up t-tests found significant reductions of GABR/β-actin, mGluR5 monomer/β-actin and FMRP/β-actin (P < 0.001, respectively), and GABR/NSE, mGluR5 monomer/NSE and FMRP/NSE (P < 0.019, P < 0.003 and P < 0.029, respectively) in BA9 of subjects with schizophrenia (Table 4, Figures 4 and 5). In subjects with bipolar disorder, follow-up t-tests found significant reductions in GABR/β-actin, mGluR5 monomer/β-actin and FMRP/β-actin (P < 0.001, respectively), and GABR/NSE, mGluR5 monomer/NSE and FMRP/NSE (P < 0.019, P < 0.003 and P < 0.029, respectively).
mGluR5 monomer/β-actin and FMRP/β-actin (P<0.024, P<0.001 and P<0.030, respectively), and GABRγ/NSE, mGluR5 monomer/NSE and FMRP/NSE (P<0.011, P<0.001 and P<0.011, respectively) (Table 4; Figures 4 and 5). There were no significant changes in protein levels for GABRγ2 or mGluR5 dimer in BA9.

Analysis of confounds for protein data in lateral cerebellum and BA9. In the analysis of protein data from lateral cerebella, no significant differences were found between groups on hemisphere side, ethnicity, gender, history of substance abuse, severity of alcohol abuse or substance abuse, post-mortem interval, age, pH or brain weight (Table 1). We also compared the groups on family history and suicide, and found significant differences (P<0.001 and P<0.029, respectively), but further analysis revealed that these factors had no significant impact on any of the results. We did find that subjects with schizophrenia and bipolar disorder had significantly longer duration of illness than did those with depression (t(47) = 2.47, P<0.018). Age of onset was significantly later for subjects with major depression compared to subjects with schizophrenia or bipolar disorder (t(41) = 3.63, P<0.001). ANOVA controlling for age of onset and duration of illness did find that subjects with depression displayed significantly higher mGluR5 dimer/NSE (F(2,31) = 4.31, P<0.02) and mGluR5 dimer/β-actin (F(2,31) = 4.31, P<0.02) than subjects with bipolar disorder or schizophrenia while controlling for duration. However, as mGluR5 dimer values did not change significantly between the groups, this finding is not meaningful.

For protein data from BA9, no significant differences were found between diagnostic groups on hemisphere side, history of substance abuse, severity of alcohol abuse or substance abuse, post-mortem interval, age or pH (Table 2). Nor did we find significant differences on use of barbiturates, opiates, amphetamines, cocaine or propoxyphene. We also compared subjects with schizophrenia versus subjects with bipolar disorder on disease duration, age of onset, use of antipsychotic, antidepressant and anticonvulsant medications.
and found no significant differences. We did find that 21.1% of bipolar patients died by suicide versus none for the other diagnostic groups ($\chi^2(2) = 10.96$, $P < 0.027$). We also found that there were significantly more female subjects ($\chi^2(2) = 10.38$, $P < 0.006$) in the bipolar group (78.9%) than in either normal controls (41.4%) or subjects with schizophrenia.

Table 4  Western blotting results for FMRP, GABR$\gamma$, mGluR5 and GABR$\beta$2 values expressed as ratios to $\beta$-actin and neuronal-specific enolase (NSE) in BA9

| ANOVA   | Control        | Schizophrenia  | Bipolar disorder |
|---------|----------------|----------------|------------------|
|         | Protein  | Protein | Protein | Protein | Protein | Protein | Protein |
| GABR$\gamma$/$\beta$-actin | 4.04  | 0.022   | 1.34 ± 0.40 | RG      | 1.06 ± 0.32 | 0.017  | 1.07 ± 0.44 | 0.024 |
| GABR$\beta$2/$\beta$-actin | 0.38  | NC      | 0.23 ± 0.17 | RG      | 0.21 ± 0.14 | NC    | 0.26 ± 0.23 | NC    |
| mGluR5 dimer/$\beta$-actin | 1.39  | NC      | 0.78 ± 0.38 | RG      | 0.57 ± 0.42 | NC    | 0.70 ± 0.49 | NC    |
| mGluR5 monomer/$\beta$-actin | 10.72 | 0.001   | 0.19 ± 0.13 | RG      | 0.089 ± 0.069 | 0.001 | 0.071 ± 0.042 | 0.001 |
| FMRP/$\beta$-actin | 3.85  | 0.027   | 0.81 ± 0.40 | RG      | 0.54 ± 0.40 | 0.018 | 0.56 ± 0.29 | 0.030 |
| $\beta$-actin | 0.19  | NC      | 7.06 ± 1.68 | RG      | 7.31 ± 1.23 | NC    | 7.29 ± 1.82 | NC    |
| GABR$\gamma$/NSE | 4.54  | 0.014   | 1.51 ± 0.40 | RG      | 1.23 ± 0.40 | 0.019 | 1.20 ± 0.36 | 0.011 |
| GABR$\beta$2/NSE | 0.54  | NC      | 0.26 ± 0.20 | RG      | 0.23 ± 0.14 | NC    | 0.30 ± 0.27 | NC    |
| mGluR5 dimer/NSE | 0.66  | NC      | 0.90 ± 0.59 | RG      | 0.72 ± 0.67 | NC    | 0.74 ± 0.50 | NC    |
| mGluR5 monomer/NSE | 8.14  | 0.001   | 0.22 ± 0.17 | RG      | 0.11 ± 0.07 | 0.003 | 0.086 ± 0.052 | 0.001 |
| FMRP/NSE    | 4.26  | 0.019   | 1.05 ± 0.55 | RG      | 0.71 ± 0.50 | 0.029 | 0.64 ± 0.36 | 0.011 |
| NSE        | 0.01  | NC      | 6.48 ± 1.79 | RG      | 6.54 ± 2.27 | NC    | 6.44 ± 2.61 | NC    |

Abbreviations: ANOVA, analysis of variance; NC, no change; RG, reference group. Bold values indicate significant ($P < 0.05$) values.

Figure 3  Expression of GABR$\gamma$/NSE (a), GABR$\beta$2/NSE (b), mGluR5 dimer/NSE (c), mGluR5 monomer/NSE (d), FMRP/NSE (e), and NSE (f) in lateral cerebella of healthy controls versus subjects with bipolar disorder, major depressive disorder and schizophrenia. Histogram bars shown as mean ± s.e., *$P < 0.05$. 

Translational Psychiatry
schizophrenia (30%). We also found higher rates of mood stabilizer use in patients with bipolar disorder (47.4%) than in patients with schizophrenia (5%) ($\chi^2(1)=9.17, P<0.002$). Further analyses controlling for gender, mood stabilizer use and suicide found the initial differences on outcome measures as a function of diagnostic groups to be unchanged.

qRT-PCR results for GABR$\gamma$, GABR$\rho$2, FMRP and mGluR5 in lateral cerebellum and BA9. For qRT-PCR experiments, all values were normalized against both $\beta$-actin and GAPDH, and these values were averaged. In the lateral cerebellum, ANOVA identified group differences for GABR$\gamma$ (GABR$\gamma$; $P<0.046$), GABR$\rho$2 (GABR$\rho$2; $P<0.017$) and GRM5 (mGluR5; $P<0.034$) (Table 5). There were significantly reduced mRNA values for GABR$\gamma$ ($P<0.016$) and GRM5 ($P<0.039$) in the lateral cerebella of subjects with schizophrenia (Table 5), similar to protein changes in the same region. GABR$\rho$2 mRNA was significantly increased ($P<0.019$) in the lateral cerebella in subjects with bipolar disorder, mirroring similar changes in protein levels, and GRM5 mRNA expression was significantly reduced ($P<0.009$) in subjects with major depression (Table 5). In BA9, ANOVA identified group differences for GABR$\rho$2 ($P<0.003$) and GRM5 ($P<0.048$) (Table 5). In BA9 of subjects with schizophrenia, there was significantly increased mRNA for GABR$\gamma$ ($P<0.03$). In BA9 of subjects with bipolar disorder, there was significantly increased mRNA for GABR$\rho$2 ($P<0.0001$) and significantly reduced mRNA for GRM5 ($P<0.04$), similar to changes in mGluR5 protein levels in the same region (Table 5). FMR1 mRNA values did not show significant changes in either of the brain areas (Table 5).

**Discussion**

The current studies demonstrate abnormal processing of mRNA and protein expression for two novel GABA$\alpha$...
receptors, \( \theta \) and \( \rho_2 \), as well as FMRP and mGluR5 in lateral cerebella and BA9 of subjects with schizophrenia and mood disorders. The most salient results included: (1) FMRP protein levels were significantly decreased in all the brain sites in schizophrenia, bipolar disorder and major depression; (2) mGluR5 protein levels were significantly reduced in all the brain sites in schizophrenia and bipolar disorder; (3) mRNA levels for mGluR5 were significantly reduced in lateral cerebellum of subjects with schizophrenia and major depression, and BA9 of subjects with bipolar disorder; (4) Protein levels for GABR\( \theta \) were reduced significantly in all the brain sites in schizophrenia, bipolar disorder and major depression; (5) mRNA levels for GABR\( \theta \) were elevated significantly in BA9 of subjects with schizophrenia, in contrast mRNA for the same receptor was decreased significantly in lateral cerebellum of subjects with schizophrenia; (6) Protein levels for GABR\( \rho_2 \) were increased significantly in lateral cerebellum of subjects with bipolar disorder and major depression; simultaneously, mRNA for the same receptor was also increased significantly in all the brain sites in subjects with bipolar disorder.

The GABR\( \theta \) gene (GABRO) is clustered with GABA\( \alpha \) receptor epsilon (GABRE) and GABA\( \alpha \) receptor alpha 3 (GABRA3) at Xq28.\(^{29}\) In rat, GABR\( \theta \) mRNA has been shown embryonically (E17/E19) to localize to the hypothalamus, tegmentum, pontine nuclei and medulla, suggesting a possible role in midbrain development.\(^{30}\) GABR\( \theta \) mRNA is expressed in multiple brain regions in human including amygdala, dorsal raphe, hippocampus, hypothalamus, locus coeruleus and substantia nigra.\(^{31}\) The locus coeruleus is relevant to psychiatric disorders, as it is the largest noradrenergic nucleus and has important roles in the regulation of anxiety states, vigilance, attention and memory functions.\(^{32}\) GABR\( \theta \) forms a functional receptor when coexpressed with alpha, beta and gamma subunits.\(^{33}\) The functional properties of GABA\( \alpha \) receptors that include the \( \theta \) subunit have not been well characterized.\(^{30}\)

Figure 5  Expression of GABR\( \theta \)/NSE (a), GABR\( \rho_2 \)/NSE (b), mGluR5 dimer/NSE (c), mGluR5 monomer/NSE (d), FMRP/NSE (e) and NSE (f) in BA9 of healthy controls versus subjects with bipolar disorder and schizophrenia. Histogram bars shown as mean ± s.e., * \( P \leq 0.05. \)
Recent studies have investigated possible associations of the gene that codes for GABR\(_y\) (GABRQ) with multiple disorders.\(^{33–36}\) However, single-nucleotide polymorphisms of GABRQ were not associated with susceptibility to bipolar disorder,\(^{33–34}\) migraine\(^{35}\) or essential tremor.\(^{36}\) However, the GABRQ-478F allele showed an association with the improvement of tremor with ethanol use among men.\(^{36}\)

The levels of GABR\(_y\) receptor protein are reduced significantly in both BA9 and lateral cerebellum of the subjects with schizophrenia (Figure 6). In contrast, mRNA for GABR\(_y\) receptor is downregulated in the lateral cerebellum, whereas in BA9 its mRNA is upregulated (Figure 6). As both mRNA and protein are concordantly downregulated in the lateral cerebellum, a severe chronic receptor deficit may be responsible for our observed results; while in BA9, increased mRNA expression may be a compensatory response to chronic receptor downregulation, suggesting that different mechanisms may be at work (Figure 6).

In subjects with bipolar disorder, GABR\(_y\) receptor protein is reduced in the lateral cerebellum while its mRNA is upregulated (Figure 7). By the same token, protein for this receptor is downregulated in BA9, with its mRNA level unchanged (Figure 7). Here, the mechanisms for these alterations may again be different in the two brain sites. In lateral cerebellum, chronic GABR\(_y\) protein downregulation could lead to upregulation of its mRNA in a feedback loop. In BA9, normal mRNA levels with decreased protein levels indicate a defective step either in processing of protein in rough endoplasmic reticulum or subsequent cell compartments (such as Golgi or secretory granules), leading to reduced protein production (Figure 7).

In subjects with major depression, although protein levels for GABR\(_y\) are reduced significantly in lateral cerebellum, its mRNA levels remain normal (Figure 8). This scenario again indicates that the deficit lies at rough endoplasmic reticulum or a subsequent cellular compartment causing the chronic receptor protein downregulation (Figure 8). In the absence of available BA9 tissue, the fate of GABR\(_y\) in major depression will await future determinations.

Recent studies have investigated possible associations of the gene that codes for GABR\(_r\) (GABRR2) with multiple disorders.\(^{33–36}\) However, single-nucleotide polymorphisms of GABRQ were not associated with susceptibility to bipolar disorder,\(^{33–34}\) migraine\(^{35}\) or essential tremor.\(^{36}\) However, the GABRQ-478F allele showed an association with the improvement of tremor with ethanol use among men.\(^{36}\)

The levels of GABR\(_r\) receptor protein are reduced significantly in both BA9 and lateral cerebellum of the subjects with schizophrenia (Figure 6). In contrast, mRNA for GABR\(_r\) receptor is downregulated in the lateral cerebellum, whereas in BA9 its mRNA is upregulated (Figure 6). As both mRNA and protein are concordantly downregulated in the lateral cerebellum, a severe chronic receptor deficit may be responsible for our observed results; while in BA9, increased mRNA expression may be a compensatory response to chronic receptor downregulation, suggesting that different mechanisms may be at work (Figure 6).

In subjects with bipolar disorder, GABR\(_r\) receptor protein is reduced in the lateral cerebellum while its mRNA is upregulated (Figure 7). By the same token, protein for this receptor is downregulated in BA9, with its mRNA level unchanged (Figure 7). Here, the mechanisms for these alterations may again be different in the two brain sites. In lateral cerebellum, chronic GABR\(_r\) protein downregulation could lead to upregulation of its mRNA in a feedback loop. In BA9, normal mRNA levels with decreased protein levels indicate a defective step either in processing of protein in rough endoplasmic reticulum or subsequent cell compartments (such as Golgi or secretory granules), leading to reduced protein production (Figure 7).

In subjects with major depression, although protein levels for GABR\(_r\) are reduced significantly in lateral cerebellum, its mRNA levels remain normal (Figure 8). This scenario again indicates that the deficit lies at rough endoplasmic reticulum or a subsequent cellular compartment causing the chronic receptor protein downregulation (Figure 8). In the absence of available BA9 tissue, the fate of GABR\(_r\) in major depression will await future determinations.

The gene that codes for GABR\(_r\)2 (GABRR2) is localized to 6q15.\(^{37}\) GABR\(_r\)2 mRNA is widely distributed in the brain, including prefrontal cortex, hippocampus and cerebellum.\(^{38,39}\) In adult rat cerebellum, GABR\(_r\)2 has been localized to

---

### Table 5 qRT-PCR results for GABRQ, GABRR2, GRM5 and FMR1 in lateral cerebella, and BA9 of subjects with schizophrenia and mood disorders

| Lateral cerebellum | Schizophrenia | Bipolar disorder | Major depression |
|-------------------|--------------|------------------|------------------|
| **Gene**         | **ANOVA**    | **Fold change**  | **P**            |
| GABRQ            | 0.046        | 0.64             | **0.016**        |
| GABRR2           | 0.017        | 1.33             | 0.11             |
| GRM5             | 0.034        | 0.49             | **0.039**        |
| FMR1             | 0.099        | 0.65             | 0.16             |

| BA9              | **Schizophrenia** | **Bipolar disorder** | **Major depression** |
|------------------|-------------------|----------------------|----------------------|
| **Gene**         | **ANOVA**         | **Fold change**      | **P**                |
| GABRQ            | 0.075             | 1.43                 | **0.03**             |
| GABRR2           | 0.003             | 1.21                 | 0.32                 |
| GRM5             | 0.048             | 1.05                 | 0.68                 |
| FMR1             | 0.705             | 0.88                 | 0.31                 |

Abbreviations: ANOVA, analysis of variance; FMR1, fragile X mental retardation 1; NTA, no tissue available; qRT-PCR, quantitative real-time polymerase chain reaction.

Note: for lateral cerebella, ANOVA is based on six comparisons: C versus S, C versus B, C versus D, S versus B, S versus D and B versus D.

For BA9, ANOVA based on three comparisons: C versus S, C versus B and S versus B.

Bold values indicate significant (\(P<0.05\)) values.
Purkinje cells and basket-like cells only.\textsuperscript{40} GABR\textsubscript{rho2} has been shown to associate with \textalpha{}1 and \gamma{}2 receptor subunits.\textsuperscript{41} In cerebellum, GABA\textsubscript{A} receptors that include the \rho{}2 subunit help mediate a component of phasic inhibitory GABAergic transmission at interneuron–Purkinje cell synapses.\textsuperscript{42}

A recent study has demonstrated an association between a single-nucleotide polymorphism of \textit{GABRR2} (GABR\textsubscript{rho2}) (rs1570932) and a component of the bipolar phenotype, namely bipolar patients with psychotic symptoms, similar to those experienced by subjects with schizophrenia.\textsuperscript{33} A second study found an single-nucleotide polymorphism (rs12201676) associated with bipolar disorder that is flanked by \textit{GABRR1} (15 kb away) and \textit{GABRR2} (17 kb away) genes.\textsuperscript{43} \textit{GABRR2} has also been associated with alcoholism.\textsuperscript{44}

Levels of GABR\textsubscript{rho2} mRNA and protein did not change in lateral cerebellum or BA9 of subjects with schizophrenia (Figure 6). However, in subjects with bipolar disorder, a concordant and significant increase was observed in mRNA and protein levels of GABR\textsubscript{rho2} in lateral cerebellum, indicating chronic upregulation in gene and protein product in this disorder (Figure 7). Interestingly, in BA9 of bipolar subjects, GABR\textsubscript{rho2} mRNA levels were also elevated significantly, but no protein change was observed (Figure 7). In major depression, GABR\textsubscript{rho2} protein levels were also elevated but without any change in mRNA, indicating abnormalities in processing GABR\textsubscript{rho2} protein in rough endoplasmic reticulum compartment or subsequent cellular stations (Figure 8). Thus, GABR\textsubscript{rho2} changes were confined to brains of subjects with mood disorders and were not seen in schizophrenia and, at least in the case of bipolar disorder, reflect upregulation of GABR\textsubscript{rho2} mRNA/protein.

The \textit{FMR1} gene is located at Xq27.3. FMRP has been shown to localize in multiple regions of neurons, including the soma, dendrites, synaptic spines and the axon.\textsuperscript{11,45,46} FMRP controls multiple post-transcriptional events, including splicing, nuclear export and translation.\textsuperscript{46,47} FMRP protein is significantly downregulated in schizophrenia, bipolar disorder and major depression in lateral cerebellum,\textsuperscript{18} and in BA9 for subjects with schizophrenia and bipolar disorder in the absence of any mRNA abnormalities (Figures 6–8). This
picture is similar to what we have described in idiopathic cases of schizophrenia without evidence of any effects in the gene for FMRP, and thus replicative of the post-transcriptional abnormalities affecting protein synthesis (Figure 9). Changes in mRNA expression do not always correlate with similar changes in protein expression, including expression of FMRP. A recent study found that in subjects with the FMR1 premutation (expanded 5’ CGG repeat, but without full symptoms of FXS), there were both significantly increased FMR1 mRNA and significantly reduced levels of FMRP. Similarly, the recent findings of Kovács et al. demonstrated the downregulation of FMRP protein levels in the absence of any change in FMR1 mRNA or expansion of the 5’ CGG triplet repeat in peripheral blood lymphocytes of subjects with schizophrenia. As reduced FMRP expression has been identified in four major psychiatric disorders, subjects with the post-transcriptional abnormalities that may be responsible for this reduction would have a major impact on the etiology and treatment of these disorders. Additionally, verification of reduced FMRP protein levels in peripheral blood lymphocytes of subjects with schizophrenia confirm our data at least in schizophrenia, and validate our additional new findings of reduced FMRP in BA9 of subjects with schizophrenia.

The gene for mGluR5 is located at 11q14.2-q14.3. mGluR5, like other metabotropic glutamate receptors contains seven membrane-spanning domains and a large extracellular N-terminus and are G-protein coupled. Metabotropic glutamate receptors are found throughout the CNS, with high concentrations in cerebral cortex, hippocampus, striatum, hypothalamus, midbrain, cerebellum, medulla and pons. There were concordant and significant reductions in levels of mRNA and protein for mGluR5 in lateral cerebellum of subjects with schizophrenia (Figure 6). In BA9, despite significant reductions in protein levels, mRNA levels were normal (Figure 6). Thus, protein levels for mGluR5 were downregulated in both brain sites in schizophrenia. In a similar vein, mGluR5 protein levels were reduced significantly in both lateral cerebellum and BA9 in subjects with bipolar disorder despite normal mRNA levels, indicating post-transcriptional abnormalities in the pathway for mGluR5 protein synthesis (Figure 7). Interestingly, in lateral cerebellum of subjects with major depression, despite downregulated mRNA for mGluR5, the protein levels were normal (Figure 8). It is possible that unknown mechanisms affecting transit for protein rescue the product for release, despite low turnover for its mRNA, in major depression.

Recently, Matosin et al. showed no significant alteration in mGluR5-binding density or mGluR5 protein levels in dorsolateral prefrontal cortex of subjects with schizophrenia. However, close inspection of their western blotting data showed highly oversaturated bands for the monomeric mGluR5 protein levels for both control and subjects with schizophrenia, potentially masking any differences between the two groups. Although several other reports did not show any change in mGluR5 protein or mRNA in prefrontal cortex of subjects with schizophrenia, these results could be due to the use of different analytic techniques or brain regional effects. However, other reports have reported the decreases in mGluR5 mRNA in prefrontal cortex of subjects with schizoaffective disorder and in those with major depression, supporting our current data showing significant decreases in mGluR5 protein levels in lateral cerebellum and BA9 of subjects with schizophrenia and bipolar disorder, and decreases in mRNA levels in lateral cerebella of subjects with schizophrenia and major depression, and BA9 of subjects with bipolar disorder. Additionally, we have previously observed increased expression of mGluR5 protein in BA9 and cerebellar vermis of children with autism (Figure 9). However, although there is a great deal of overlap in the symptomologies of autism and FXS, there is less overlap between FXS and schizophrenia, and mood disorders.

Interactions between the aforementioned four proteins may alter GABAergic transmission. The cytoplasmic domains of GABRA1 and GABRA2 interact with MAP1B (Figure 9). Disruption of p-MAP1B interactions leads to a doubling of the inward current of GABAA receptors from bipolar cells in retinal slices in the presence of low levels of GABA. MAP1B mRNA is targeted by FMRP (Figure 9), and in FMR1-knock out mice there is an abnormal upregulation of MAP1B. With reduced expression of FMRP, one might speculate that there would be increased expression of MAP1B in subjects with schizophrenia and mood disorders. However, a preliminary study involving anterior cingulate cortex found reduced expression of MAP1B protein in subjects with bipolar disorder, with no change in subjects with schizophrenia or major depression. Further experiments involving multiple brain sites would be required to see if this is a regional difference or there is a global reduction. Altered expression of MAP1B could in turn cause changes in GABAergic neurotransmission through GABA receptors that contain p subunits. Currently, we do not know of a link between FMRP and GABRA1 (Figure 9). No changes in GABRA1 mRNA were identified among the GABA receptors subunits that show reduced expression in animal models of FXS.

In conclusion, FMRP is significantly downregulated in the lateral cerebella and BA9 from subjects with schizophrenia, bipolar disorder and major depression, potentially causing GABA receptor changes and altered expression of mGluR5 in the three disorders in the absence of any FMR1 chromosomal abnormalities. Additionally, we have identified selective abnormalities in mRNA and protein levels of two novel GABA receptors, namely GABRA1 and GABRA2, in subjects with schizophrenia and mood disorders. These changes could potentially explain changes in GABAergic transmission and consequent deficits associated with these disorders including anxiety, panic, and impaired learning and memory. Our results also identify potential novel targets for future pharmacologic intervention. Lastly, despite significance and novelty of these results, the study should be considered exploratory, requiring further future confirmation in other brain sites.

Conflict of interest

The authors declare no conflicts of interest. Dr Fatemi has patents related to Reelin as a marker of psychiatric disorders. He derives no income as yet from these patents.

Acknowledgements. Grant support by the National Institutes of Mental Health (Grant no. 1R01MH086000-01A2) to SHF is gratefully acknowledged. SHF is also supported by the Bernstein Endowed Chair in Adult Psychiatry. Tissue samples...
from the Stanley Medical Research Institute and assistance with demographic information from Dr Edwin Fuller-Torrey and Dr Maree J Webster to SHF is gratefully acknowledged. Tissue samples from the Harvard Brain Tissue Resource Center, which is supported in part by PHS grant number R24 MH088855 is gratefully acknowledged.

Disclaimer. NMHH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report and in the decision to submit the paper for publication.

1. Gonzalez-Burgos G, Fish KN, Lewis DA. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neurot Plasma 2011; 16: 383–406.
2. Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 2011; 16: 2198–2206.
3. Heulens I, D’Hulst C, Braat S, Rooms L, Kooiy RF. Involvement and therapeutic potential of metabotropic glutamate receptors in the fragile X syndrome. ScientificWorldJournal 2010; 19: 246–247.
4. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluroxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berlin) 2005; 186: 362–372.
5. Santoro G, Costa G. SSRIs act as selective brain steroidogenic stimulants (SSBSS) at low doses that are inactive on 5-HT reuptake. Curr Op Pharmacol 2009; 9: 24–30.
6. Brandon NJ, Smart TG, Moss SJ. Regulation of GABA receptors by protein phosphorylation. J Biol Chem 2009; 284: 127–132.
7. D’Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA et al. Correction of the GABAergic system in the fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. J Neurosci Res 2006; 84: 105–106.
8. Dolen G, Osterweil E, Shankaranarayana Rao BS, Smith GB, Auerbach D, Chattaraj S et al. Correction of fragile X syndrome in mice. Neuroiat 2007; 96: 141–146.
9. Centonze D, Rossi S, Mercaldo V, Napoli I, Cotti MT, De Chiara V et al. Abnormal striatal GABA transmission in the mouse model for fragile X syndrome. Biochem Pharmacol 2010; 79: 620–626.
10. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27: 370–377.
11. de Vijf FM, Levengra J, Der van Linde HC, Koekkoek SK, De Zeeuw CI, de Zeeuw CI et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2006; 21: 127–132.
12. Doerr A, Dufour A, Mercaldo V, Van Dam D, De Deyn PP, Hassan BA et al. Increased levels of GABAergic receptors in the mGluR5 KO mouse model. Nat Neurosci 2008; 11: 127–132.
13. Fernandez F, Esposito T, Lea RA, Colson NJ, Ciccocioppo A, Gianfrancesco F et al. Investigation of gamma-aminobutyric acid (GABA) A receptors and membrane susceptibility. BMC Med Genet 2008; 9: 109.
14. Garcia-Martinez M, Martinez C, Alonso-Navarro H, Benito-Leon J, Lorenzo-Betancor O, Pastor P et al. GABAergic system in the Fmr1 KO mouse model: alterations in the expression of GABAergic markers and risk for essential tremor. Pharmacogenet Genomics 2011; 21: 436–439.
15. Ma DO, Whitehead PL, Menold MM, Martin ER, Ashley-Koch AE, Mei H et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. J Hum Genet 2005; 50: 377–388.
16. Akiulkaitis A, Paljig M, Weigelus K, Schmidt M, Ern R, Paul et al. GABA receptor subunit expression in the developing rat brain. Brain Res Dev Brain Res 2005; 154: 15–23.
17. Boe-Grabot E, Roudabashi M, Basleci L, Tramu G, Bloch G, Garret M. Expression of GABA receptor subunits in the developing rat brain. J Neurochem 1998; 70: 899–907.
18. Rizzo A, Armellin M, Franzo J, Chiaruttini C, Nistri A, Tongeong E. Expression and dendritic mRNA localization of GABAA receptor subunit m2c2 subunits in developing rat brain and spinal cord. Eur J Neurosci 2002; 15: 1747–1758.
19. Milligan CJ, Buckley NJ, Garret M, Deuchars J, Deuchars SA. Evidence for inhibition mediated by coassembly of GABAA and GABAC receptor subunits in native central neurons. J Neurosci 2004; 24: 7241–7250.
20. Harvey VL, Duguid IC, Krasel C, Stephens GJ. Evidence that GABA subunits contribute to functional ionotropic GABA receptors in mouse cerebellar Purkinje cells. J Physiol 2006; 577: 127–139.
21. Wang KS, Liu XF, Angram N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and mood disorders: a postmortem study. J Autism Dev Disord 2011a; 38: 1136–1143.
51. Matosin N, Frank E, Deng C, Huang X-F, Newell KA. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr Res 2013; 146: 170–176.

52. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005; 57: 123–131.

53. Corti C, Xuereb JH, Crepaldi L, Corsi M, Michelin F, Ferraguti F. Altered levels of glutamatergic receptors and Na⁺/K⁺-ATPase-α1 in the prefrontal cortex of subjects with schizophrenia. Schizophr Res 2011; 128: 7–14.

54. Ohnuma T, Tessler S, Arai H, Fauli RL, McKenna PJ, Emson PC. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res 2000; 85: 24–31.

55. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 2000; 47: 22–28.

56. Volk DW, Eggan SM, Lewis DA. Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 2010; 167: 1489–1498.

57. Deuschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by (11)C)ABP688 PET and postmortem study. Am J Psychiatry 2011; 168: 724–734.

58. Billups D, Hanley JG, Orme M, Attwell D, Moss SJ. GABAC receptor sensitivity is modulated by interaction with MAP1B. J Neurosci 2001; 20: 8643–8650.

59. Lu R, Wang H, Liang Z, Ku L, O’ donnell WT, Li W et al. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA 2004; 101: 15201–15206.

60. Bouras C, Kóvari E, Hof PR, Riederer BM, Giannakopoulos P. Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol 2001; 102: 373–379.

Theta and rho2 GABA receptors and schizophrenia
SH Fatemi et al.